person · Reporting owner
Harrell James Archie Jr
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Commercial Officer | December 10, 2021 | December 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date December 10, 2021 · Filed December 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,766 |
Reported balance
After 2021-12-10 transaction · row 1
1 source rowRow 1 · 2021-12-10 · Purchase · Acquired 1,093 · Balance 36,766 F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 14, 2021 17:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 1,093 | $1.57 | $1,716.01 |
DisclosureSEC source: 0001879785-21-000038 · edgar.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,766 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:02 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 7,493 | $2.28 | $17,084.04 |
DisclosureSEC source: 0001192482-21-000499 · edgar.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,673 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 16:07 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001192482-21-000117 · edgar.xml · derivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-01-26 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:17 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 171 | $2.28 | $389.54 |
DisclosureSEC source: 0001192482-20-000820 · edgar.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,180 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 21:42 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 6,391 | $2.28 | $14,558.70 |
DisclosureSEC source: 0001192482-20-000494 · edgar.xml · nonDerivative · entry 2 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,009 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 21:42 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 10,000 | $2.50 | $25,000.00 |
DisclosureSEC source: 0001192482-20-000494 · edgar.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,618 Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 18:02 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 268,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001578563-20-000014 · primary_doc.xml · derivative · entry 2 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,000 Underlying: Common Stock · 268,000 shares Expires 2030-04-09 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 16:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 3,064 | $2.85 | $8,724.74 |
DisclosureSEC source: 0001578563-19-000038 · primary_doc.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,618 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 19:51 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 4,398 | $2.85 | $12,523.31 |
DisclosureSEC source: 0001578563-19-000021 · primary_doc.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Exec. VP, Mktg & External Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,554 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 18:59 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001578563-19-000009 · primary_doc.xml · derivative · entry 2 Harrell James Archie Jr · CIK 0001738462 · Exec. VP, Mktg & External Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| December 10, 2018 Filed Dec 11, 2018 17:31 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | PurchaseCommon Stock | 4,156 | $2.85 | $11,834.21 |
DisclosureSEC source: 0001738462-18-000004 · primary_doc.xml · nonDerivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Exec. VP, Mktg & External Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,156 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| May 07, 2018 Filed May 8, 2018 16:34 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0001738462-18-000003 · primary_doc.xml · derivative · entry 1 Harrell James Archie Jr · CIK 0001738462 · Exec. VP, Mktg & External Comm 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The grant shall vest one-fourth on May 7, 2019, and the remaining three-fourth vest in 36-monthly installments beginning on June 7, 2019, provided that Mr. Harrell is then an employee of the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.